Offering is 8% Cumulative Perpetual Preferred Stock, Series A. 8.00% of the $25.00 per share liquidation preference per annum (equivalent to $2.00 per annum per share). Dividends on the Preferred Stock shall be payable quarterly on the 15th day of March, June, September and December of each year, commencing on June 15 , 2018.
Boenning & Scattergood, Inc.
American Capital Partners, Joseph Gunnar & Co.
Genprex is a clinical stage gene therapy company developing a new approach to treating cancer, based upon their novel proprietary technology platform, including their initial product candidate, Oncoprex immunogene therapy, or Oncoprex.
Network 1 Financial
They are a Cayman Islands exempted company incorporated as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities.
Ladenburg Thalmann, Brookline Capital Markets